Cargando…
Application of the New Process for Unapproved Drug Use: Dilemma of Universal Health Care Coverage in Japan
Autores principales: | Nishiwaki, Satoshi, Ando, Yuichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Clinical Oncology
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882518/ https://www.ncbi.nlm.nih.gov/pubmed/31702945 http://dx.doi.org/10.1200/JGO.19.00313 |
Ejemplares similares
-
Microbiological contamination in counterfeit and unapproved drugs
por: Pullirsch, Dieter, et al.
Publicado: (2014) -
Concerns about unapproved meningococcal vaccination for eculizumab therapy in Japan
por: Tanimoto, Tetsuya, et al.
Publicado: (2014) -
The Prevalence and Cost of Unapproved Uses of Top-Selling Orphan Drugs
por: Kesselheim, Aaron S., et al.
Publicado: (2012) -
The Vexing Voyage of Vasopressin: The Consequences of Granting Market Exclusivity to Unapproved Drugs
por: Bendicksen, Liam, et al.
Publicado: (2022) -
Unapproved clinical trials in Russia: exception or norm?
por: Talantov, Petr, et al.
Publicado: (2021)